Cannabis Stock News- Investing in Cannabis and Hemp Stocks : Investor Ideas #Potcasts 551 #Cannabis News and #Stocks on the Move; (TSXV: $PKAN.V) (TSXV: $EMHV) (CSE: $EASY.C) (CSE: $IKNK.U.C) (TSXV: $KHRN.V) (OTCQX: $KHRNF)

Investor Ideas #Potcasts 551 #Cannabis News and #Stocks on the Move; (TSXV: $PKAN.V) (TSXV: $EMHV) (CSE: $EASY.C) (CSE: $IKNK.U.C) (TSXV: $KHRN.V) (OTCQX: $KHRNF)

Delta, Kelowna, BC, April 13, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2021/041321-StocksToWatch.mp3

Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/04131PKAN-EMH-EASY-IKNK-KHRN.asp

Hear the investor ideas potcast on Spotify

Hear Investor ideas cannabis potcast on iTunes

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we look at a few public company announcements.

PureK Holdings Corp‎. (TSX-V: PKAN), along with its majority-owned CBD subsidiary company, PureKana LLC, ("PureKana"), announcedt hat it has entered into a brand partnership with leading cannabis and CBD retailer Chemesis International Inc. (CSE: CSI) (OTC: CADMF), under which PureKana’s industry-leading CBD products will become available at hundreds of proprietary Chemesis kiosks throughout the United States.

As a result of this partnership, PureKana’s industry-leading range of products - including its flavored pure hemp-derived CBD oils, sleep aids, immunity boosts, vegan CBD-infused gummies, soothing CBD-infused topical creams, and CBD capsules - will become a part of the permanent product offering for Chemesis’ A.I.-powered VICKI Intelligent Self-Checkout platform.

Chemesis’ VICKI kiosks can be deployed in high traffic areas like shopping malls, workplaces, and transit hubs and feature proprietary technologies to enhance the cannabis retail experience, including age verification, loss prevention, product education, and A.I.-powered virtual assistant technologies.

"Our partnership with Chemesis accelerates our omni-channel distribution of the PureKana Brand. CBD education, innovation, and availability are foundational to our mission to enable wellness authentically every day for our loyal consumers," said Kathy Casey, CEO of PureK Holdings Corp.

"PureKana is a highly regarded brand by consumers and within the industry for their quality and well branded products," said President of Chemesis, Josh Rosenberg. "This partnership will allow Chemesis and PureKana to develop a cohesive strategy to bring high-quality products to consumers through an alternate route to market. Working with a strong brand such as PureKana, will give the VICKI platform another edge over typical brick and mortar dispensaries."

Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) has launched its new product line, SYNC™ Tabs, an innovative, naturally-flavoured ingestible offering consumers a controlled 10 mg THC dose with predictable onset and offset. This product line expands its offering under its SYNC™ Wellness brand and is the second of Emerald's Defined Dose™ products. The first provincial purchase orders have been received and, beginning April 13th, the tablets will be available to consumers at licensed cannabis retailers and online in BC, Manitoba, and Newfoundland, with Alberta to follow.

Emerald's Cannabis 2.0 and 3.0 strategy focuses on leveraging science-based innovation to serve targeted consumer preferences. This differentiated new product line builds on Emerald's commitment to offering consumers defined dosing and predictable actions that let them control their cannabis consumption experience. SYNC™ Tabs are designed in a familiar tablet form that enables convenient yet discreet cannabis use.

With 10 mg of THC, SYNC™ Tabs offer consumers the measured stringency of Emerald's Defined Dose™ standard, dissolve under the tongue in about three minutes, and provide desired effects within 20 to 30 minutes. Offset is equally controlled, occurring within approximately 90 minutes of taking the tablet. This new product line follows the introduction of Emerald's Nano Fast-Acting Spray product. Sublingual tablets add to the SYNC™ brand's line-up of non-smoking forms of cannabis products, which also include CBD and THC cannabis oils.

Designed to serve customers' use of cannabis for daily wellness routines, SYNC™ Tabs are sugar-free, gluten-free, vegan and come in two natural flavours, cherry and mint. Produced with 100-percent coconut-derived MCT oil, the products offer a sustainably-produced cannabis wellness option. Each pack contains 10 x 10 mg doses, offering 100 mg of THC in total.

"Our product development efforts are centered on providing consumers with distinctive cannabis products offering controlled, predictable actions – with greater precision of dosing and the onset and offset of effects," said Riaz Bandali, President and CEO. "We have a talented product development team that is passionate about science and innovation. They are moving additional new product lines toward launches planned for the next few months and quarters, which we expect to start positively impacting our growth."

SpeakEasy Cannabis Club Ltd. (CSE: EASY), a holder of a federal licence to cultivate, process and sell cannabis under the Cannabis Act. announced that it has entered the final stage of amending its sales license to allow the sale of its extracts and concentrates.

Founder, Marc Geen, "Extractions and concentrates are a rapidly growing and an important part of the cannabis market in Canada. We are eagerly anticipating our licence that once granted, will allow us to participate in this exciting segment of the market. With our large inventory of flower, perfect for creating extracts and concentrates, we are eager to enter the consumer extract market that will become an important part of our business for years to come. Because of our low-cost of production, we will be entering the market with the ability to be very competitive with anyone out there. These are very busy and exciting times and I am thrilled we will soon be able to show what we can do in this segment of the market."

Currently, SpeakEasy is licenced to sell its dried flower to consumers. With the addition of its expected sales amendment, the Company will be well positioned to enter the market with a robust lineup of products ranging from simple artisan style concentrates to more complex live resin vape carts. Formulations have been prepared and brands are ready to launch upon receipt of the amendment. The ability to create a large and diverse range of products and be able to enter each market with a low price point is predicted to give SpeakEasy a significant advantage over companies without an outdoor flower production area.

Keeping production and processing in-house is a critical way to keep costs low. SpeakEasy, in partnership with Frontier Labs, produces, processes and packages its product without losing margin to other companies by contracting out or taking on the cost of shipping between facilities. With SpeakEasy's goal of competing directly with "black market" pricing, keeping costs as low as possible is crucial to our success. Starting with our low-cost input material, which is expected to be among the lowest in the industry, and carrying on to finished product by using efficient, cost effective methods completed in-house, SpeakEasy is able to pass those cost savings on to consumers and be a strong competitor in the market.

Founder, Marc Geen, states, "Having a price advantage, focusing on genuine high-quality and branding that is rooted in the legacy BC market will give us the opportunity to stand out from the crowd. We are a unique company for many reasons, and I believe we will be able to make ourselves well known for all the right reasons across the country."

Ikänik Farms, Inc. (CSE: IKNK.U) announced that Pideka SAS., a wholly-owned subsidiary of Ikänik Farms, has successfully completed its cooperative agreement with SGS Colombia SAS to design, initiate, develop, and implement a normative standard for the international certification of medicinal cannabis. This certification works to establish a new baseline standard for the quality and safety of pharmaceutical grade cannabis products known as the "GPTCP", or "Good Production Transformation & Commercialization Practices Cannabis Pharma".

"Completing this collaborative certificate with SGS Colombia is a milestone achievement and a reflection of the company's dedication to best-in-class quality for the cannabis industry." said Brian Baca, CEO of Ikänik Farms.

The GPTCP certificate ensures the company maintains international standards and differentiates itself by adhering to a global benchmark standard of quality for the production cannabis.

With the collaborative development of the SGS certified seal of self-regulation and sustainability, industry best practices are promoted and fosters a competitive approach to quality, through best in class and standardized processes across the industry, providing end consumers with product confidence.

The GPTCP encompasses facets of the requirements under various standards such as the BPA, BPM, INVIMA, ICA, ISO 9001, SG-SST, EUGMP at both the national (Colombian) and international levels.

The quality certification and delivery of high-caliber products is one of the Company's key objectives, supported through operating certifications obtained for its operations, including (GACP, GMP FARMA, ISO-9001, and EUGMP)

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced that it has received UK Continuing Professional Development ("CPD") accreditation for Khiron Academy, the Company's global medical cannabis education platform.

Additionally, following its accreditation, the Company has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK and fellow founding member of Project Twenty21, to increase patient access through medical cannabis education initially. Khiron Academy will be made available to prescribers in the UK that have registered with Cellen's MedCanHub, an emerging education portal. Cellen is market leader, widely recognized for also launching the UK's first digital pain clinic, Leva.

Tejinder Virk, President of Khiron Europe, commented, "Over the last year, Khiron has seen a direct correlation between physician education and patient access. With Khiron Academy's CPD accreditation and through our strategic partnership with Cellen Therapeutics, we are positioned to reach a growing number of medical professionals, and in turn, provide patients with greater access to medical cannabis products."

Eric Bystrom, CEO of Cellen commented, "We are pleased to be joining forces with Khiron on educating prescribing specialists in the UK. Khiron is a clear global leader in medical cannabis education. We share common values in improving patient lives by educating doctors and optimizing the standard of medical care. Our aim is to create a practical guide for responsibly prescribing patients with safe and efficacious medical cannabis products."

In the UK, Khiron continues to leverage educational materials developed by the Company to train medical professionals in Latin America, along with clinical data from thousands of Khiron patients. In addition to Cellen's MedCanHub (accessible to medical professionals at https://medcanhub.cellenhealth.com/ ), Khiron Academy is available to members of the Medical Cannabis Clinicians Society (MCCS) and core to the training of prescribing specialists for Project Twenty21, a 20,000-patient observational study backed Drug Science in UK.

To date, the Company has trained nearly 1000 medical professionals in Latin America and the UK. Over the last year, physicians trained by Khiron in Latin America have issued over 13,000 prescriptions, with a compound monthly growth rate of nearly 50%. Khiron Academy will be a platform for sharing the Company's clinical expertise, in conjunction with clinical data arising from Khiron's wholly-owned clinics in LatAm.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Play Music and most audio platforms available.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com